title: [Survival analysis of HIV/AIDS patients with access to highly antiretroviral therapy in Ningbo during 2004-2015].
abstract: Objective:To understand the epidemiology characteristics and survival status of HIV/AIDS patients with access to highly antiretroviral therapy (HAART) in Ningbo during 2004-2015.Methods:A retrospective cohort study was conducted among HIV/AIDS patients diagnosed between 2004 and 2015. Life Tables were used to estimate survival rates, and Kaplan-Meier curve with Log rank test were used to describe the survival curves and the Cox proportional hazard model was used to determine predictors of mortality.Results:Of the subjects, the median age when starting HAART was 35 years (IQR: 27-45 years). Most of them were males, local residents, married, infected through heterosexual sexual transmission, and their baseline CD4T cells counts were mainly ≤200 cells/μl, and most of them were at clinical stageⅠ(WHO). The cumulative survival rate was 96.75% for the first year, 92.36% for the fifth year, 91.87% for the seventh year and 90.02% for the tenth year. The risk of the mortality was 17.34 times higher for those aged >60 years compared with those aged ≤20 years (95%CI: 2.11-142.71), 2.83 times higher for those at clinical stage Ⅳ(WHO) compared with those at clinical stageⅠ (WHO) (95% CI: 1.67-4.80) and 3.26 times higher for those with drug resistance compared with those without drug resistance (95%CI: 1.77-6.01). Blood transmission, lower CD4+T cell level, BMI <18.5, unmarried were the risk factors for the mortality.Conclusions:The effect of HAART was obvious in the HIV/AIDS patients in Ningbo, their survival rate was high. The finding indicated that it is necessary to strengthen the health care for old population and health education about AIDS prevention and control, and conduct large scale screening. Early discovery, early diagnosis, early treatment and improving treatment compliancy are still the effective ways to reduce the mortality.
authors.affiliation: Medical College of Ningbo University, Ningbo 315211, China.
authors.forename: J H
authors.initials: JH
authors.lastname: Zhang
authors.affiliation: Institute for STD/HIV Control and Prevention, Ningbo Center for Disease Control and Prevention, Ningbo 315010, China.
authors.forename: H L
authors.initials: HL
authors.lastname: Li
authors.affiliation: Institute for STD/HIV Control and Prevention, Ningbo Center for Disease Control and Prevention, Ningbo 315010, China.
authors.forename: H B
authors.initials: HB
authors.lastname: Shi
authors.affiliation: Institute for STD/HIV Control and Prevention, Ningbo Center for Disease Control and Prevention, Ningbo 315010, China.
authors.forename: H B
authors.initials: HB
authors.lastname: Jiang
authors.affiliation: Institute for STD/HIV Control and Prevention, Ningbo Center for Disease Control and Prevention, Ningbo 315010, China.
authors.forename: H
authors.initials: H
authors.lastname: Hong
authors.affiliation: Institute for STD/HIV Control and Prevention, Ningbo Center for Disease Control and Prevention, Ningbo 315010, China.
authors.forename: H J
authors.initials: HJ
authors.lastname: Dong
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000401:mortality; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes; D003141:Communicable Diseases; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality; D020010:Heterosexuality; D006801:Humans; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D015996:Survival Rate